Regulus Therapeutics Inc. (NASDAQ:RGLS) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

Regulus Therapeutics Inc. (NASDAQ:RGLS) Files An 8-K Results of Operations and Financial Condition
Item 2.02

On March 12, 2020, we issued a press release announcing our financial results for the fourth quarter and year ended December 31, 2019. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached exhibit shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended

(d) Exhibits.

99.1    Press release issued by Regulus Therapeutics Inc. on March 12, 2020 relating to financial results


Regulus Therapeutics Inc. Exhibit
EX-99.1 2 d857165dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates FDA Removal of Partial Clinical Hold for Phase I Multiple Ascending Dose Study of RGLS4326 Reinitiated Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD Closed $26 Million Second Tranche of Private Financing LA JOLLA,…
To view the full exhibit click here

About Regulus Therapeutics Inc. (NASDAQ:RGLS)

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.